Home Oncology Immunotherapies

Immunotherapies

Latest
Killer T-lymphocyte attacking a cancer cell
Immunotherapies

Immune Cell Activity in the Blood Can Predict Tumor Response to...

ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]
Immunotherapies

New Immunotherapy Checkpoint Targets Identified in Myeloid Cells

Glioma - brain tumor
Immunotherapies

CAR-T Cell Therapy for Glioblastoma Shows Early Promise

Brain cancer, conceptual artwork
Immunotherapies

New Combination Immunotherapy Approach Shows Promise Treating Medulloblastoma

Breast cancer cells, SEM
Immunotherapies

Immunotherapy Before Surgery May Be Beneficial in High-Risk Breast Cancer

Metastatic breast cancer
Immunotherapies

Researchers Find New Immune Cell Type in Breast Cancer That Could...

ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]
Immunotherapies

A Mechanism that Regulates PD-L1 Production Suggests New Therapeutic Approaches

Killer T-lymphocyte attacking a cancer cell
Immunotherapies

Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion

CART Cell Cancer Immunotherapy
Immunotherapies

A Triple-Pronged Approach to CAR T Therapy

Killer T-lymphocyte attacking a cancer cell
Immunotherapies

Immunotherapy Linked to Thyroid Dysfunction

Load more

New Products

View More
Load more
Copyright © 2020 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up